We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
HHS has decided not to recommend substantive policy, administrative or legislative changes related to barriers to the availability of pediatric medical devices, but instead will propose conducting a needs assessment to “determine the scope of unmet device needs in the pediatric population,” according to a recently released report.
HHS Secretary Michael Leavitt wants to change the way the government pays for prescription drugs under Medicaid as part of a larger plan to eliminate wasteful spending on the program.
HHS Secretary Michael Leavitt announced proposed regulations Jan. 27 that would facilitate the use of electronic prescriptions when the Medicare drug benefit takes effect next January.
NIH employees will be prohibited from collaborating with the pharmaceutical and biotechnology industries under a new supplemental ethics regulation issued Feb 1.
Federal regulators are preparing to conduct more thorough examinations of drug products as part of an evidence-based approach to medicine that will drive the implementation of the Medicare Rx benefit, which is slated to take effect next year.
While both paid and unpaid consulting arrangements between NIH scientists and private industry will end under the agency’s new ethics rule, some observers believe informal communications should continue while others predict a bleak future for public-private partnerships.
HHS Secretary Michael Leavitt has called for eliminating wasteful spending on Medicaid, including by changing the way the government pays for prescription drugs under the program.
Federal regulators are preparing to conduct much more thorough examinations of drug products as part of an evidence-based approach to medicine that will drive the implementation of the Medicare Rx benefit, which is slated to take effect next year.
The FDA issued an emergency-use authorization (EUA) Jan. 31 for military use of anthrax vaccine, marking the first time the agency has used its EUA power since it was granted the emergency authority last summer with the passage of Project BioShield.